$MRNA $MRK CNBC: Moderna Jumps as Merck Extends Partnership on Cancer Vaccine


(Bloomberg) – Covid-19 vaccine maker Moderna Inc. rose the most in two months after Merck & Co. said it would exercise an option to maintain its partnership with the biotech company on a messenger RNA cancer vaccine. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------>

Moderna will receive $250 million from Merck in exchange for joint development and future commercialization of the vaccine, which is in mid-stage testing as a treatment for high-risk melanoma, the companies said Wednesday in a statement.


Merck and Moderna’s agreement, initially entered in 2016, involves Moderna’s mRNA-4157/V940 cancer vaccine that’s designed to stimulate an immune response to cancer based on the DNA sequence of the patient’s tumor. The companies are testing the experimental vaccine in tandem with Merck’s cancer blockbuster Keytruda, which brought in more than $17 billion last year. Keytruda blocks proteins that prevent the immune system from recognizing tumors.

$MRNA daily, weekly, and monthly charts

$MRK daily, weekly, and monthly charts

1 Like